NDRA News and Press, ENDRA Life Sciences Inc. From 11/14/22

ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Yvonne Briggs - Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Renau...

Endra Life Sciences press release ( NASDAQ: NDRA ): Q3 GAAP EPS of -$0.05. Operating expenses increased to $3.4 million in the third quarter of 2022 from $2.7 million in the same period in 2021. The increase was primarily due to higher spending related to commercializing t...

Conference call begins at 4:30 p.m. Eastern time today ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reported financial results for the three and nine months ended September 30, 2022, and provided a b...

Endra Life Sciences ( NASDAQ: NDRA ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.06 Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For further...

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today announced that the company will report financial results for the third quarter of 2022 on Monday, November 14, 2022 after the close of trading on the U.S. fin...

ENDRA Life Sciences Inc. (NASDAQ: NDRA) , a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that the United States Patent and Trademark Office has issued two new ENDRA patents, U.S. Patent No. 11456518 (the ‘518 patent) titled “Method ...

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that management will present a company overview at the H.C. Wainwright 6 th Annual NASH Investor Conference being held October 17, 20...

ENDRA Life Sciences ( NASDAQ: NDRA ) on Thursday said it would submit a De Novo request to the U.S. FDA in the coming weeks for its TAEUS liver disease monitoring system. The FDA's De Novo process gives companies a pathway to classify medical devices which are not alre...

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces an update to its plan to submit a De Novo request for the TAEUS system to the U.S. Food and Drug Administration (FDA). “I&...

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS ® ), announces that management will present a company overview at the H.C. Wainwright 24 th Annual Global Investment Conference being held September...